Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CAD | P27708 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523894 | 1.00 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL30741902 | 0.87 | KDM4E (0.33) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL6555890 | 0.86 | KDM4E (0.36) | ALDH1A1MAPTSMN1; SMN2KDM4ETHRB | |
| SCHEMBL6555886 | 0.86 | KDM4E (0.36) | ALDH1A1MAPTSMN1; SMN2KDM4ETHRB | |
| SCHEMBL30741904 | 0.84 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2RECQLHPGD | |
| SCHEMBL2953807 | 0.82 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL2953811 | 0.82 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL19176028 | 0.82 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL21554072 | 0.82 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL2953812 | 0.82 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313653-A1 | GUEST/HOST INCLUSION COMPLEXES CONTAINING S-NITROSOGLUTATHIONE AND METHODS OF USE THEREOF | UNIV VIRGINIA COMMONWEALTH (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | disclosed |
| EP-4561372-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4536264-A1 | GUEST/HOST INCLUSION COMPLEXES CONTAINING S-NITROSOGLUTATHIONE AND METHODS OF USE THEREOF | Virginia Commonwealth University (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024026124-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | PETERSON MATTHEW (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023239551-A1 | GUEST/HOST INCLUSION COMPLEXES CONTAINING S-NITROSOGLUTATHIONE AND METHODS OF USE THEREOF | VIRGINIA COMMNWEALTH UNIVERSITY (US) | 2023-12-14 | — | — | WO | disclosed |
| US-6613937-B2 | In particular for transdermal, oral, rectal and inhalational application | TSIKAS DIMITRIOS (DE) | 2003-09-02 | — | — | US | disclosed |
| US-20020091102-A1 | S-nitroso- and S-nitro-N-acyl-L-cysteine ester derivatives as pharmalogically active agents and pharmaceutical compositions containing said compounds | TSIKAS DIMITRIOS (DE) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | AHCY, MGMT, CBS | CYP1A2 1349/4885CYP2C9 307/4885CYP2C19 170/4885 |
| US-20020091102-A1 | S-nitroso- and S-nitro-N-acyl-L-cysteine ester derivatives as pharmalogically active agents and pharmaceutical compositions containing said compounds | NNMT, NNT, CBS | CYP1A2 684/4885CYP2C9 266/4885CYP2C19 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.